Kong Lingming, Zhu Xiaoli, Zhang Liyi, Chen Shengdong
Center of Mental Disorder Prevention and Treatment, No. 904 Hospital, Changzhou, China.
Department of Neurological, No. 904 Hospital, Changzhou, China.
Indian J Psychiatry. 2023 Jul;65(7):715-719. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_385_22. Epub 2023 Jul 12.
First episode and drug naive schizophrenia (SZ) patients comorbid with major depressive episode and generalized anxiety disorder (GAD) comorbid with major depressive disorder (MDD) are common in clinical practice, overlapping symptomatology during first presentation of MDD, SZ and GAD challenged the diagnostic process.
This study aimed to investigate the differentiation value of peripheral microRNA-26b expression in 52 patients of MDD, SZ, and GAD, respectively, and 52 controls. Quantitative real-time reverse transcription polymerase chain reaction was used to further verify aberrant miRNAs of previous identified in MDD and investigate expression level of these peripheral miRNAs in SZ and GAD.
The expression levels of miR-26b and miR-4743 were significantly upregulated and of miR-4498, miR-4485, and miR-1972 had no significant difference. There were no significant differences of expression levels of miR-26b, miR-4498, miR-4485, and miR-1972 except miR-4743 between SZ patients and control group and of miR-26b, miR-1972, miR-4498, and miR-4485 between GAD group and the controls. The receiver operating characteristic (ROC) curve of miR-26b in MDD patients showed that its sensitivity and specificity for diagnosis were 0.540 and 0.830, respectively, with the area under curve (AUC) being 0.728; the ROC of miR-26b for SZ and MDD differentiation showed that its sensitivity and specificity were 0.580 and 0.710, respectively, with AUC being 0.631; the ROC of miR-26b for GAD and MDD differentiation suggested that sensitivity and specificity were 0.560 and 0.750, respectively, with AUC being 0.637.
MiR-26b might have potential value of differentiation biomarker for MDD, SZ, and GAD.
首发且未服用过药物的精神分裂症（SZ）患者合并重度抑郁发作，以及广泛性焦虑障碍（GAD）合并重度抑郁症（MDD）在临床实践中很常见，MDD、SZ和GAD首次出现时症状重叠，给诊断过程带来了挑战。
本研究旨在分别调查52例MDD、SZ和GAD患者以及52例对照者外周血微小RNA-26b（miR-26b）表达的鉴别价值。采用定量实时逆转录聚合酶链反应进一步验证先前在MDD中鉴定出的异常微小RNA，并研究这些外周微小RNA在SZ和GAD中的表达水平。
miR-26b和miR-4743的表达水平显著上调，而miR-4498、miR-4485和miR-1972的表达水平无显著差异。SZ患者与对照组之间，除miR-4743外，miR-26b、miR-4498、miR-4485和miR-1972的表达水平无显著差异；GAD组与对照组之间，miR-26b、miR-1972、miR-4498和miR-4485的表达水平也无显著差异。MDD患者中miR-26b的受试者工作特征（ROC）曲线显示，其诊断的敏感性和特异性分别为0.540和0.830，曲线下面积（AUC）为0.728；miR-26b用于区分SZ和MDD时，其敏感性和特异性分别为0.580和0.710，AUC为0.631；miR-26b用于区分GAD和MDD时，敏感性和特异性分别为0.560和0.750，AUC为0.637。
miR-26b可能对MDD、SZ和GAD具有作为鉴别生物标志物的潜在价值。
